Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr 1;45(2):269-272.
doi: 10.1097/FTD.0000000000001050. Epub 2022 Nov 9.

Subtherapeutic Exposure of Ganciclovir in Children Despite Appropriate Dosing: A Short Communication

Sjanene Marfil  1 , Anne-Grete Märtson  1   2 , Marlous Toren-Wielema  1 , Coretta Leer-Buter  3 , Elisabeth H Schölvinck  4 , Jan-Willem C Alffenaar  5   6   7 , Daan J Touw  1 , Marieke G G Sturkenboom  1
Affiliations

Subtherapeutic Exposure of Ganciclovir in Children Despite Appropriate Dosing: A Short Communication

Sjanene Marfil et al. Ther Drug Monit. .

Abstract

Therapeutic drug monitoring (TDM) results for ganciclovir in 12 different treatment episodes showed large intraindividual and interindividual variabilities in the trough concentration and area under the 24-hour concentration-time curve (AUC24). Despite adequate valganciclovir dosing, subtherapeutic concentrations were found in 30% of the treatment episodes. A decrease in viral load was observed regardless of subtherapeutic exposure. These findings show the need for target concentration evaluation and assessment of the applicability of ganciclovir TDM in children.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

FIGURE 1.
FIGURE 1.
Individual line plots show intraindividual and interindividual variability in Cmin (A) and AUC24 (B); x-axis represents the day of sampling and y-axis (A) Cmin (mg/L); (B) AUC24 (mg h/L); BSA: Body surface area (m2); colors indicate valganciclovir dose administered 24 hours before sampling. Red dashed lines represent lower and upper target concentrations (A) or AUC24 (B).
See this image and copyright information in PMC

References

    1. Kotton CN, Kumar D, Caliendo AM, et al. . Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation. 2013;96:333–360. - PubMed
    1. Paya C, Humar A, Dominguez E, et al. . Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transpl. 2004;4:611–620. - PubMed
    1. Takahata M, Hashino S, Nishio M, et al. . Occurrence of adverse events caused by valganciclovir as pre-emptive therapy for cytomegalovirus infection after allogeneic stem cell transplantation is reduced by low-dose administration. Transpl Infect Dis. 2015;17:810–815. - PubMed
    1. Humar A, Lebranchu Y, Vincenti F, et al. . The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Amer J Transpl. 2010;10:1228–1237. - PubMed
    1. Märtson A-G, Edwina AE, Kim HY, et al. . Therapeutic drug monitoring of ganciclovir: where are we? Ther Drug Monit. 2022;44:138. - PMC - PubMed

Publication types